Neuroimaging of Rapidly Progressive Dementias, Part 1: Neurodegenerative Etiologies

REFERENCES

1. 1.↵
   1. Kelley BJ,
   2. Boeve BF,
   3. Josephs KA

   . Rapidly progressive young-onset dementia. Cogn Behav Neurol 2009;22:22–27

   CrossRefPubMed
2. 2.↵
   1. Heinemann U,
   2. Gawinecka J,
   3. Schmidt C,
   4. et al

   . Differential diagnosis of rapid progressive dementia. Eur Neurol Rev 2010;5:21–28
3. 3.↵
   1. Geschwind MD,
   2. Haman A,
   3. Miller BL

   . Rapidly progressive dementia. Neurol Clin 2007;25:783–807, vii

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Geschwind MD,
   2. Shu H,
   3. Haman A,
   4. et al

   . Rapidly progressive dementia. Ann Neurol 2008;64:97–108

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Frisoni GB,
   2. Pievani M,
   3. Testa C,
   4. et al

   . The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007;130:720–30

   Abstract/FREE Full Text
6. 6.↵
   1. Mueller S,
   2. Keeser D,
   3. Reiser M,
   4. et al

   . Functional and structural MR imaging in neuropsychiatric disorders, part 1: imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuradiol 2011;33:1845–50

   PubMed
7. 7.↵
   1. Burton E,
   2. Barber R,
   3. Mukaetova-Ladinska E,
   4. et al

   . Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132:195–203

   Abstract/FREE Full Text
8. 8.↵
   1. O'Riordan S,
   2. McMonagle P,
   3. Janssen JC,
   4. et al

   . Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002;59:1108–10

   CrossRef
9. 9.↵
   1. Adair JC,
   2. Lee RR

   . Abnormal fluid-attenuated inversion recovery signal foci in the splenium of a patient with presenilin-1 mutation. AJNR Am J Neuroradiol 2004;25:1864–65

   FREE Full Text
10. 10.↵
    1. Kantarci K

    . 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007;80(spec No. 2):S146–52

    Abstract/FREE Full Text
11. 11.↵
    1. Kantarci K,
    2. Weigand SD,
    3. Petersen RC,
    4. et al

    . Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007;28:1330–39

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Yang Y,
    2. Jia HM,
    3. Liu BL

    . (E)-5-styryl-1H-indole and (E)-6-styrylquinoline derivatives serve as probes for β-amyloid plaques. Molecules 2012;17:4252–65

    CrossRefPubMed
13. 13.↵
    1. Jack CR Jr..

    Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344–61

    CrossRefPubMed
14. 14.↵
    1. Firbank MJ,
    2. Blamire AM,
    3. Teodorczuk A,
    4. et al

    . Diffusion tensor imaging in Alzheimer's disease and dementia with Lewy bodies. Psychiatry Res 2011;194:176–83

    CrossRefPubMed
15. 15.↵
    1. Gaig C,
    2. Valldeoriola F,
    3. Gelpi E,
    4. et al

    . Rapidly progressive diffuse Lewy body disease. Mov Disord 2011;26:1316–23

    CrossRefPubMed
16. 16.↵
    1. Burton EJ,
    2. Mukaetova-Ladinska EB,
    3. Perry RH,
    4. et al

    . Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol Aging 2012;33:1228–36

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Taylor JP,
    2. O'Brien J

    . Neuroimaging of dementia with Lewy bodies. Neuroimaging Clin N Am 2012;22:67–81, vii

    CrossRefPubMed
18. 18.↵
    1. Watson R,
    2. Blamire AM,
    3. O'Brien JT

    . Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord 2009;28:493–506

    CrossRefPubMed
19. 19.↵
    1. Bozzali M,
    2. Falini A,
    3. Cercignani M,
    4. et al

    . Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005;128:1595–604

    Abstract/FREE Full Text
20. 20.↵
    1. Warr L,
    2. Walker Z

    . Identification of biomarkers in Lewy-body disorders. Q J Nucl Med Mol Imaging 2012;56:39–54

    PubMed
21. 21.↵
    1. Knopman DS,
    2. Boeve BF,
    3. Parisi JE,
    4. et al

    . Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005;57:480–88

    CrossRefPubMedWeb of Science
22. 22.↵
    1. van der Flier W,
    2. Scheltens P

    . Use of laboratory and imaging investigations in dementia. J Neurol Neurosurg Psychiatry 2005;76:v45

    FREE Full Text
23. 23.↵
    1. Gordon E,
    2. Rohrer J,
    3. Kim L,
    4. et al

    . Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010;74:666–73

    CrossRef
24. 24.↵
    1. Tokumaru AM,
    2. Saito Y,
    3. Murayama S,
    4. et al

    . Imaging-pathologic correlation in corticobasal degeneration: imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuradiol 2009;30:1884–92

    Abstract/FREE Full Text
25. 25.↵
    1. Boxer AL,
    2. Geschwind MD,
    3. Belfor N,
    4. et al

    . Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63:81–86

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Mascalchi M,
    2. Vella A,
    3. Ceravolo R

    . Movement disorders: role of imaging in diagnosis. J Magn Reson Imaging 2012;35:239–56

    CrossRefPubMed
27. 27.↵
    1. Morris HR,
    2. Wood NW,
    3. Lees AJ

    . Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J 1999;75:579–84

    Abstract/FREE Full Text
28. 28.↵
    1. Stamelou M,
    2. Knake S,
    3. Oertel WH,
    4. et al

    . Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011;258:549–58

    CrossRefPubMed
29. 29.↵
    1. Paviour DC,
    2. Price SL,
    3. Jahanshahi M,
    4. et al

    . Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006;129:1040–49

    Abstract/FREE Full Text
30. 30.↵
    1. Righini A,
    2. Antonini A,
    3. De Notaris R,
    4. et al

    . MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease—imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuradiol 2004;25:927–32

    Abstract/FREE Full Text
31. 31.↵
    1. Taki M,
    2. Ishii K,
    3. Fukuda T,
    4. et al

    . Evaluation of cortical atrophy between progressive supranuclear palsy and corticobasal degeneration by hemispheric surface display of MR images: imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuradiol 2004;25:1709–14

    Abstract/FREE Full Text
32. 32.↵
    1. Seppi K,
    2. Schocke MF,
    3. Wenning GK,
    4. et al

    . How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm 2005;112:1625–34

    CrossRefPubMed
33. 33.↵
    1. Horimoto Y,
    2. Aiba I,
    3. Yasuda T,
    4. et al

    . Cerebral atrophy in multiple system atrophy by MRI. J Neurol Sci 2000;173:109–12

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Brooks DJ,
    2. Seppi K

    , for the Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949–64

    CrossRefPubMed
35. 35.↵
    1. Okamoto K,
    2. Tokiguchi S,
    3. Furusawa T,
    4. et al

    . MR features of diseases involving bilateral middle cerebellar peduncles: imaging techniques and their application in mild cognitive impairment and Alzheimer disease. AJNR Am J Neuradiol 2003;24:1946–54

    Abstract/FREE Full Text
36. 36.↵
    1. Seppi K,
    2. Poewe W

    . Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010;20:29–55

    CrossRefPubMed
37. 37.↵
    1. Kwon KY,
    2. Choi CG,
    3. Kim JS,
    4. et al

    . Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease. Mov Disord 2007;22:2352–58

    CrossRefPubMed
38. 38.↵
    1. Horimoto Y,
    2. Aiba I,
    3. Yasuda T,
    4. et al

    . Longitudinal MRI study of multiple system atrophy: when do the findings appear, and what is the course? J Neurol 2002;249:847–54

    CrossRefPubMedWeb of Science
39. 39.↵
    1. von Lewinski F,
    2. Werner C,
    3. Jorn T,
    4. et al

    . T2*-weighted MRI in diagnosis of multiple system atrophy: a practical approach for clinicians. J Neurol 2007;254:1184–88

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Shiga K,
    2. Yamada K,
    3. Yoshikawa K,
    4. et al

    . Local tissue anisotropy decreases in cerebellopetal fibers and pyramidal tract in multiple system atrophy. J Neurol 2005;252:589–96

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Blain CR,
    2. Barker GJ,
    3. Jarosz JM,
    4. et al

    . Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006;67:2199–205

    CrossRef
42. 42.↵
    1. Pellecchia MT,
    2. Barone P,
    3. Mollica C,
    4. et al

    . Diffusion-weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov Disord 2009;24:689–96

    CrossRefPubMed
43. 43.↵
    1. Schocke MF,
    2. Seppi K,
    3. Esterhammer R,
    4. et al

    . Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575–80

    CrossRef
44. 44.↵
    1. Seppi K,
    2. Schocke MF,
    3. Mair KJ,
    4. et al

    . Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 2006;31:240–45

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Seppi K,
    2. Schocke MF,
    3. Prennschuetz-Schuetzenau K,
    4. et al

    . Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006;21:847–52

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Nicoletti G,
    2. Lodi R,
    3. Condino F,
    4. et al

    . Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679–87

    Abstract/FREE Full Text
47. 47.↵
    1. Montoya A,
    2. Price BH,
    3. Menear M,
    4. et al

    . Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 2006;31:21–29

    PubMedWeb of Science
48. 48.↵
    1. Hobbs NZ,
    2. Barnes J,
    3. Frost C,
    4. et al

    . Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036–41

    Abstract/FREE Full Text
49. 49.↵
    1. Jurgens CK,
    2. Jasinschi R,
    3. Ekin A,
    4. et al

    . MRI T2 hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr 2010;2. pii
50. 50.↵
    1. Versluis MJ,
    2. van der Grond J,
    3. van Buchem MA,
    4. et al

    . High-field imaging of neurodegenerative diseases. Neuroimaging Clin N Am 2012;22:159–71, ix

    CrossRefPubMed
51. 51.↵
    1. Aylward EH,
    2. Liu D,
    3. Nopoulos PC,
    4. et al

    . Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 2012;71:822–28

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Klöppel S,
    2. Henley SM,
    3. Hobbs NZ,
    4. et al

    . Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience 2009;164:205–19

    CrossRefPubMed
53. 53.↵
    1. Aylward EH

    . Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007;72:152–58

    CrossRefPubMedWeb of Science